Gyre Therapeutics Cash Flow Statement (2010-2026) | GYRE

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	-19.90M	-25.22M	-20.39M	-14.54M	51.63M	-4.88M	-27.90M	4.22M	3.77M	7.51M	-100.98M	9.94M	4.54M	2.86M	-1.64M	3.73M	1.58M	5.94M	-22.10M	-9.86M
Share-based Compensation (Quarter)	0.98M	0.71M	0.68M	0.52M	0.35M	0.22M	12.28M	0.21M	0.09M	0.10M	6.88M	0.01M	0.02M	0.24M	0.57M	0.51M	0.91M	1.15M	4.60M	2.58M
Deferred Taxes (Quarter)								-0.33M	-0.23M	-0.20M	-0.40M	-0.31M	-0.10M		-0.59M	-0.19M	-0.30M	-0.53M	-0.09M	-0.74M
Gains from Sales and Divestitures (Quarter)
Gains from Investment Securities (Quarter)	3.24M	1.30M	2.60M	2.78M	1.31M	8.91M	17.04M	0.46M			-5.29M	-4.29M	0.00M	18.55M	2.08M	3.36M	17.81M	0.02M	-0.00M	0.21M
Asset Writedowns and Impairment (Quarter)				0.20M
Non-cash Items (Quarter)	1.34M	5.30M	3.90M	1.31M	1.38M	4.33M	12.67M	7.31M	7.41M	7.61M	444.20M	0.10M	18.09M	4.70M	190.38M	10.80M	15.64M	15.10M	15.94M	16.17M
Cash from Operations (Quarter)	-20.12M	-21.60M	-17.68M	-12.05M	-12.29M	-7.28M	42.30M	10.42M	4.53M	7.58M	3.36M	2.88M	-5.49M	1.73M	-2.76M	-0.10M	2.06M	4.68M	-5.62M	3.20M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
Amortization of Deferred Charges (Quarter)
Depreciation & Amortization (CF) (Quarter)	0.04M	0.09M	0.12M	0.11M	0.07M	0.04M	0.87M	0.28M	0.31M	0.19M	0.30M	0.41M	0.23M	0.45M	0.46M	0.54M	0.64M	0.65M	0.66M	0.67M
Change in Working Capital
Change in Receivables (Quarter)	0.96M	-0.86M	0.70M	-1.05M	-0.56M						-1.10M				1.15M				4.83M	-8.57M
Change in Inventory (Quarter)								-0.53M	-0.12M	-0.92M	-0.18M	0.67M	0.72M	0.64M	0.12M	1.54M	0.95M	-0.07M	1.21M	1.01M
Change in Account Payables (Quarter)	-1.12M	2.03M	2.56M	-1.71M	-3.67M	-1.00M	6.27M	0.16M	0.37M	0.00M	-0.34M	-0.02M	-0.06M	0.03M	-0.19M	0.01M	-0.05M	0.48M	-0.43M	0.14M
Change in Accured Expenses (Quarter)	0.69M	0.81M	-5.15M	1.04M	-4.72M	-0.64M	6.23M	1.03M	1.93M	-3.00M	1.49M	-1.97M	-0.07M	-1.55M	2.09M	4.44M	-2.36M	-3.51M	2.38M	0.68M
Change in Taxes (Quarter)								1.92M	-1.23M	2.50M	-0.18M	1.42M	-4.19M	0.54M	0.07M	-2.27M	0.51M	1.54M	0.26M	0.14M
Other Working Capital Changes (Quarter)	569.00	569.00	-2.75M	0.05M	0.05M	0.05M	-0.74M	0.01M	0.01M	0.01M	-1.12M	1.52M	0.06M	0.20M	-1.76M	5.54M	-5.81M	-0.03M	0.51M	0.91M
Investing Activities
Capital Expenditures (Quarter)		0.49M						1.74M	2.48M	1.97M	2.32M	0.23M	1.46M	0.69M	-0.07M	0.12M	0.26M	0.67M	0.14M	0.18M
Sales of Property, Plant and Equipment (Quarter)							0.05M			0.36M	0.17M	0.05M	0.22M	-0.01M	0.14M	0.00M	0.02M		0.01M	0.01M
Change in Intangibles (Quarter)							-54.99M	0.07M	0.00M	0.00M	0.00M				0.81M	0.70M	0.02M	0.01M	-0.00M	0.01M
Change in Acquisitions & Divestments (Quarter)	11.05M	7.53M	2.87M	2.50M												11.19M			4.24M	10.07M
Cash from Investing Activities (Quarter)	10.70M	7.04M	2.87M	2.50M	52.87M		-69.19M	-7.65M	-8.05M	-5.40M	1.34M	-7.22M	-8.27M	-2.39M	-2.00M	1.97M	-3.04M	-1.25M	1.85M	-3.06M
Financing Activities
Other financing activities (Quarter)														0.05M	0.37M	0.12M	1.68M	-0.32M
Cash from Financing Activities (Quarter)	-0.00M	0.10M		0.02M		-45.03M		-7.76M	-3.50M	-1.48M	15.24M	0.66M	0.16M	0.32M	0.96M	1.34M	22.35M	0.36M	0.32M	0.02M
Dividend Payments
Dividends Paid - Common (Quarter)								7.76M	3.50M	1.50M
Additional items
Exchange Rate Effect (Quarter)								0.20M	-0.90M	0.17M	0.23M	-0.05M	-0.08M	0.11M	-0.26M	0.05M	0.05M	0.12M	0.13M	0.28M
Change in Cash (Quarter)	-9.42M	-14.46M	-14.81M	-9.53M	40.58M	-52.30M	16.23M	2.97M	-4.42M	2.35M	7.43M	-3.72M	-13.69M	-0.23M	-4.05M	3.23M	21.45M	3.91M	-3.33M	0.43M
Free Cash Flow (Quarter)	-20.12M	-22.09M	-17.68M	-12.05M	-12.29M	-7.28M	42.30M	8.68M	2.06M	5.61M	1.04M	2.65M	-6.95M	1.03M	-2.69M	-0.22M	1.80M	4.01M	-5.77M	3.02M
Net Cash Flow (Quarter)	-9.42M	-14.46M	-14.81M	-9.53M	40.58M	-52.30M	-26.89M	-4.99M	-7.02M	0.70M	19.94M	-3.68M	-13.61M	-0.34M	-3.80M	3.21M	21.37M	3.79M	-3.46M	0.17M

Research Tools

Gyre Therapeutics Cash Flow Statement (2010-2026) | GYRE

Create an account

Sign In

Reset Password